modafinil has been researched along with Multiple Myeloma in 1 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This double-blind, placebo-controlled phase 3 trial evaluated the efficacy of armodafinil in MM patients with evidence of moderate fatigue." | 9.20 | A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. ( Andreu-Vieyra, C; Berenson, JR; Charu, V; Chen, CS; Nassir, Y; Sanani, S; Schlutz, M; Shamasunder, HK; Swift, RA; Vescio, R; Woliver, TB; Yellin, O, 2015) |
| "This double-blind, placebo-controlled phase 3 trial evaluated the efficacy of armodafinil in MM patients with evidence of moderate fatigue." | 5.20 | A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. ( Andreu-Vieyra, C; Berenson, JR; Charu, V; Chen, CS; Nassir, Y; Sanani, S; Schlutz, M; Shamasunder, HK; Swift, RA; Vescio, R; Woliver, TB; Yellin, O, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berenson, JR | 1 |
| Yellin, O | 1 |
| Shamasunder, HK | 1 |
| Chen, CS | 1 |
| Charu, V | 1 |
| Woliver, TB | 1 |
| Sanani, S | 1 |
| Schlutz, M | 1 |
| Nassir, Y | 1 |
| Swift, RA | 1 |
| Andreu-Vieyra, C | 1 |
| Vescio, R | 1 |
1 trial available for modafinil and Multiple Myeloma
| Article | Year |
|---|---|
A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.
Topics: Adult; Aged; Benzhydryl Compounds; Cross-Over Studies; Double-Blind Method; Fatigue; Female; Humans; | 2015 |